These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219 [TBL] [Abstract][Full Text] [Related]
3. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640 [TBL] [Abstract][Full Text] [Related]
4. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743 [TBL] [Abstract][Full Text] [Related]
5. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130 [TBL] [Abstract][Full Text] [Related]
6. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
7. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083 [TBL] [Abstract][Full Text] [Related]
8. Highly specific SARS-CoV-2 main protease (M Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E Antiviral Res; 2024 Jul; 231():105969. PubMed ID: 39053514 [TBL] [Abstract][Full Text] [Related]
9. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496 [TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors. Takashita E; Fujisaki S; Morita H; Nagata S; Miura H; Nagashima M; Watanabe S; Takeda M; Kawaoka Y; Hasegawa H Antiviral Res; 2023 Aug; 216():105671. PubMed ID: 37451629 [TBL] [Abstract][Full Text] [Related]
16. Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses. Jeong JH; Choi JH; Kim BK; Min SC; Chokkakula S; Oh S; Park JH; Shim SM; Kim EG; Choi YK; Lee JY; Baek YH; Song MS Antiviral Res; 2023 Aug; 216():105669. PubMed ID: 37437781 [TBL] [Abstract][Full Text] [Related]